GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBryan Dechairo - COOKevin Feeley - CFOKatherine Stueland - CEO and PresidentSubbu Nambi - Director of Equity Research DepartmentSabrina Dunbar - Head of Investor RelationsConference Call ParticipantsDavid Westenberg - Senior Research Analyst and Managing DirectorKeith Hinton - Director and Equity Research AnalystTycho Peterson - Managing Director and Research AnalystMark Massaro - Managing Director and Life Science ...

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Speaker4Good day, and thank you for standing by. Welcome to the GeneDx third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one-one on your telephone. You will then hear an automated message advising your hand is raised. To start a question, please ...

BREAKING: Gold Prices, Stocks Continue To Slide With third-quarter earnings on tap for Oct. 28, Wall Street has genomics and rare-disease diagnostics leader GeneDx (WGS) squarely on its radar. Here are four reasons investors should take a close look at GeneDx stock. The U.S. Food and Drug Administration on Monday granted Breakthrough Device Designation for the company's ExomeDx and GenomeDx testing. The tests aim to identify causes of life-threatening diseases or genetic disorders, helping to diagnose sympt ...